Bruton tyrosine kinase degradation as a therapeutic strategy for cancer

The covalent Bruton tyrosine kinase (BTK) inhibitor ibrutinib is highly efficacious against multiple B-cell malignancies. However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy. We hypothesized that small-molecule–in...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood
Main Authors: Dobrovolsky, Dennis, Wang, Eric S., Morrow, Sara, Leahy, Catharine, Faust, Tyler, Nowak, Radosław P., Donovan, Katherine A., Yang, Guang, Li, Zhengnian, Fischer, Eric S., Treon, Steven P., Weinstock, David M., Gray, Nathanael S.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2019
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6396177/
https://ncbi.nlm.nih.gov/pubmed/30545835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-07-862953
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker